discovered that immunohistochemical expression of CD31, pVEGFR1 and VEGFR1 and -2 in the primary tumor may be a predictor of a good response to sunitinib in mRCC patients treated with this medicine [37]. The gene discussed is FLT1; the disease is neoplasm.